

# FACULTY BIOGRAPHIES + REFERENCES



## ELIZABETH PRECHTEL DUNPHY, DNP, RN, ANP-BC, AOCN

Nurse Practitioner, Medical Oncology  
Abramson Cancer Center  
Penn Presbyterian Medical Center  
Advanced Senior Lecturer B  
Biobehavioral and Health Sciences Division  
Adult Oncology Specialty Minor/Post Masters Certificate  
University of Pennsylvania School of Nursing  
Philadelphia, Pennsylvania

Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, is a medical oncology nurse practitioner who specializes in gastrointestinal malignancies at the Abramson Cancer Center at Penn Presbyterian Medical Center and Advanced Senior Lecturer B at the University of Pennsylvania School of Nursing in Philadelphia. Additionally, she serves on the faculty for the Adult Oncology Minor/Post Masters Certificate program. Dr. Dunphy received her master's degree from the University of Pennsylvania and her Doctor of Nursing Practice degree from Villanova University in Villanova, Pennsylvania.

Dr. Dunphy has been member of various committees for the Oncology Nursing Certification Corporation, including the inaugural Chairperson for Individual Learning Needs Assessment (ILNA) Development Committee for the Advanced Oncology Certified Nurse Practitioner ILNA Program. She has authored several articles and book chapters and was Co-Editor of the *Guide to Cancer Immunotherapy* published by the Oncology Nursing Society. Dr. Dunphy has presented locally and nationally on topics related to gastrointestinal oncology.



## CATHERINE FRENETTE, MD, FAST, AGAF, FAASLD

Medical Director, Liver Transplantation  
Scripps Center for Organ Transplantation  
Scripps Green Hospital  
Director, Liver and Hepatocellular Cancer Program  
Scripps MD Anderson Cancer Center  
La Jolla, California

Catherine Frenette, MD, FAST, AGAF, FAASLD is Medical Director of Liver Transplantation at the Scripps Center for Organ Transplantation at Scripps Green Hospital in La Jolla, California, and of the Liver and Hepatocellular Cancer Program at Scripps MD Anderson Cancer Center in San Diego, California. She received her medical degree from Rush Medical College in Chicago, Illinois, before completing training in Internal Medicine at the Scripps Mercy Hospital in San Diego before completing training in Gastroenterology with a focus on Transplant Hepatology at the Scripps Clinic in La Jolla.

Dr. Frenette is a Fellow of the American Society of Transplantation and the American Gastroenterological Association. She has worked diligently to provide excellent medical care to patients with end-stage liver disease and liver cancer. Dr. Frenette has been principle or co-investigator for multiple clinical trials related to liver disease and liver cancer, and she serves a key role in the training of gastroenterology fellows and internal medicine residents. She has served the community through the American Liver Foundation, where she serves as Vice-Chair of the local Medical Advisory Committee and is on the National Executive Committee.



## ANDREW X. ZHU, MD, PHD

Director, Jiahui International Cancer Center  
Shanghai, China  
Director Emeritus, Liver Cancer Program  
Massachusetts General Hospital Cancer Center  
Professor of Medicine, Harvard Medical School  
Boston, Massachusetts

Andrew X. Zhu, MD, PhD, is Director of the Jiahui International Cancer Center in Shanghai, China, Director Emeritus of the Liver Cancer Program at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.

Dr. Zhu's research focuses on developing more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma; developing novel molecular and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance; and defining and characterizing known or novel genetic mutations in HCC and cholangiocarcinoma, assessing their potential correlation with clinical outcomes and as therapeutic targets, and dissecting the molecular mechanisms of drug resistance to targeted therapy. As a widely published author, he has served as a principal investigator in many clinical trials in HCC, cholangiocarcinoma, and other gastrointestinal cancers.

Dr. Zhu is an internationally recognized authority in HCC and cholangiocarcinoma, and he led early efforts of developing several molecularly targeted, immunotherapeutic agents and combination regimens in liver cancers that led to regulatory approval and studying the predictive and surrogate molecular and imaging biomarkers. Dr. Zhu is a founding member of the International Liver Cancer Association, a Fellow of the American College of Physicians, and a member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on a number of national committees and task forces in the research and study of liver cancer and disease, and he has received several awards for his work, including the V Foundation Translational Research Award, the Lorenzo Cappussotti Award, and the Jonathan Kraft Translational Award.

## REFERENCES

### ABSTRACTS, PUBLICATIONS, AND WEBSITES

Abou-Alfa GK, Meyer T, Cheng AL, et al. [Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma](#). *N Engl J Med*. 2018;379(1):54-63.

Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. [Systemic treatment for advanced hepatocellular carcinoma](#). *Liver Cancer*. 2019;8(5):341-358.

Bruix J, Qin S, Merle P, et al. [Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment \(RESORCE\): a randomised, double-blind, placebo-controlled, phase 3 trial](#). *Lancet*. 2017;389(10064):56-66.

Cheng A-L, Finn RS, Qin S, et al. [Phase III trial of lenvatinib \(LEN\) vs sorafenib \(SOR\) in first-line treatment of patients \(pts\) with unresectable hepatocellular carcinoma \(uHCC\)](#). *J Clin Oncol*. 2017;35(15 suppl):4001-4001.

Cheng AL, Kang YK, Chen Z, et al. [Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial](#). *Lancet Oncol*. 2009;10(1):25-34.

Cheng AL, Qin S, Ikeda M, et al. [IMbrave150: Efficacy and safety results from a phase III study evaluating atezolizumab \(atezo\) + bevacizumab \(bev\) vs sorafenib \(Sor\) as first treatment \(tx\) for patients \(pts\) with unresectable hepatocellular carcinoma \(HCC\)](#). *Annals of Oncology*. 2019;30(suppl 9):ix186-ix187.

Crocenzi TS, El-Khoueiry AB, Yau TC, et al. [Nivolumab \(nivo\) in sorafenib \(sor\)-naive and -experienced pts with advanced hepatocellular carcinoma \(HCC\): CheckMate 040 study](#). *J Clin Oncol*. 2017;35(15\_suppl):4013-4013.

Finn RS, Qin S, Ikeda M, et al. [Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma](#). *N Engl J Med*. 2020; 382(20):1894-1905.

Johnston MP, Khakoo SI. [Immunotherapy for hepatocellular carcinoma: Current and future](#). *World J Gastroenterol*. 2019;25(24): 2977-2989.

Kallini JR, Gabr A, Thorlund K, et al. [Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review](#). *Cardiovasc Intervent Radiol*. 2017;40(7):1033-1043.

Kudo M, Finn RS, Qin S, et al. [Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial](#). *Lancet*. 2018;391(10126):1163-1173.

Lee, A., Lee, F. [Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check](#). *Front. Med*. 2020; 14(3):273-283.

Llovet JM, Ricci S, Mazzaferro V, et al. [Sorafenib in advanced hepatocellular carcinoma](#). *N Engl J Med*. 2008;359(4):378-390.

National Cancer Institute Surveillance, Epidemiology, and End Results Program. [Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer](#). National Cancer Institute website. <https://seer.cancer.gov/statfacts/html/livibd.html>. Accessed September 16, 2020.

National Comprehensive Cancer Network (NCCN). [NCCN Guidelines for Hepatobiliary Cancers. \(Version 5.2020\)](#) [https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf) Accessed September 16, 2020.

## REFERENCES (CONT.)

National Comprehensive Cancer Network (NCCN). [NCCN Guidelines for Management of Immunotherapy-Related Toxicities. \(Version 1.2020\)](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf). [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf) Accessed September 16, 2020.

NCT01658878. [ClinicalTrials.gov website](https://clinicaltrials.gov/ct2/show/NCT01658878). <https://clinicaltrials.gov/ct2/show/NCT01658878>. Last updated June 30, 2020. Accessed September 9, 2020.

NCT03434379. [ClinicalTrials.gov website](https://clinicaltrials.gov/ct2/show/NCT03434379). <https://clinicaltrials.gov/ct2/show/NCT03434379>. Last updated August 6, 2020. Accessed September 8, 2020.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. [Interpreting the significance of changes in health-related quality-of-life scores](#). *J Clin Oncol*. 1998;16(1):139-144.

Villanueva A. [Hepatocellular Carcinoma](#). *N Engl J Med* 2019;380:1450-1462.

Vogel A, Saborowski A. [Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma](#). *Cancer Treat Rev*. 2020;82:101946.

Wai Ling Khoo TS, Rehman A, Olynyk JK. [Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma](#). *Hepatocellular Carcinoma [Internet]*. Brisbane (AU): Codon Publications; 2019.

Yau T, Kang Y-K, Kim T-Y, et al. [Nivolumab \(NIVO\) + ipilimumab \(IPI\) combination therapy in patients \(pts\) with advanced hepatocellular carcinoma \(aHCC\): Results from CheckMate 040](#). *J Clin Oncol*. 2019;37(15\_suppl):4012-4012.

Zhu AX, Finn RS, Edeline J, et al. [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib \(KEYNOTE-224\): a non-randomised, open-label phase 2 trial](#). *Lancet Oncol*. 2018;19(7):940-952.

Zhu AX, Kang Y, Yen C, et al. [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased  \$\alpha\$ -fetoprotein concentrations \(REACH-2\): a randomised, double-blind, placebo-controlled, phase 3 trial](#). *Lancet Oncol*. 2019; 20(2):282-296.

Zhu AX, Kang Y-K, Yen C-J, et al. [REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma \(HCC\) and elevated baseline alpha-fetoprotein \(AFP\) following first-line sorafenib](#). *J Clin Oncol*. 2018;36(15 suppl):4003-4003.

## SYSTEMIC DRUG APPROVAL AND PRESCRIBING INFORMATION

### Tyrosine kinase inhibitors (TKIs)

[Cabozantinib \(Cabometyx®\) Prescribing Information](#). FDA website. Last updated July 2020. Accessed September 16, 2020.

[Cabozantinib \(Cabometyx®\) Approval Letter](#). FDA website. January 2019. Accessed September 16, 2020.

[Lenvatinib \(Lenvima®\) Prescribing Information](#). FDA website. Last updated February 2020. Accessed September 16, 2020.

[Lenvatinib \(Lenvima®\) Approval Letter](#). FDA website. August 2018. Accessed September 16, 2020.

[Regorafenib \(Stivarga®\) Prescribing Information](#). FDA website. Last updated June 2020. Accessed September 16, 2020.

## REFERENCES (CONT.)

[Regorafenib \(Stivarga®\) Approval Letter](#). FDA website. April 2017. Accessed September 16, 2020.

[Sorafenib \(Nexavar®\) Prescribing Information](#). FDA website. Last updated July 2020. September 16, 2020.

[Sorafenib \(Nexavar®\) Approval Letter](#). FDA website. November 2007. Accessed September 16, 2020.

### Immunotherapies

[Atezolizumab \(Tecentriq®\) Prescribing Information](#). FDA website. Last updated July 2020. Accessed September 16, 2020.

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic HCC. ASCO Post website. <https://www.ascopost.com/news/may-2020/fda-approves-atezolizumab-plus-bevacizumab-for-patients-with-unresectable-or-metastatic-hcc/>. Updated May 31, 2020. Accessed September 16, 2020.

[Ipilimumab \(Yervoy®\) Prescribing Information](#). FDA website. Last updated August 2020. Accessed September 16, 2020.

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. FDA website. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma>. Updated March 11, 2020. Accessed September 16, 2020.

[Nivolumab \(Opdivo®\) Prescribing Information](#). FDA website. Last updated June 2020. Accessed September 16, 2020.

[Nivolumab \(Opdivo®\) Approval Letter](#). [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2017/125554Orig1s041ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2017/125554Orig1s041ltr.pdf). FDA website. September 22, 2017. Accessed September 16, 2020.

[Pembrolizumab \(Keytruda®\) Prescribing Information](#). FDA website. Last updated June 2020. Accessed September 16, 2020.

FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. FDA website. <https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma>. Updated December 14, 2018. Accessed September 16, 2020.

### Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors

[Bevacizumab \(Avastin®\) Prescribing Information](#). FDA website. Last updated May 2020. Accessed September 16, 2020.

[Ramucirumab \(Cyramza®\) Prescribing Information](#). FDA website. Last updated July 2020. Accessed September 16, 2020.

[Ramucirumab \(Cyramza®\) Approval Letter](#). FDA website. May 2019. Accessed September 16, 2020.